TAC1 and prostate cancer: Consistent with these findings showing an association between loss of NKA in carcinoma and cancer progression, an isoform of the β subunit of NKA has been found to be a tumour-suppressor [58] and its expression along with total NKA activity has been found to be markedly reduced in prostate cancer [55] and kidney cancer [59].